Literature DB >> 16809030

Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.

Mads Nikolaj Holten-Andersen1, Hans Jørgen Nielsen, Steen Sørensen, Vibeke Jensen, Nils Brünner, Ib Jarle Christensen.   

Abstract

The aim of this study was to investigate whether the pre- and postoperative plasma levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) were associated with outcome in colorectal cancer (CRC). Pre- and postoperative plasma TIMP-1 from 280 curatively resected CRC patients and carcinoembryonic antigen (CEA) in corresponding serum samples were measured and correlated with patient outcome (death, local recurrence (LR) and distant metastases (DM)). The results showed that the course of plasma TIMP-1 from pre- to postoperative levels correlated with patient outcome (P=0.005). However, postoperative plasma TIMP-1 alone was strongly associated with patient outcome, high TIMP-1 predicting short survival (P=0.002). Combining postoperative TIMP-1 and CEA demonstrated that high TIMP-1 and CEA levels predicted poor outcome (P<0.0001); multivariate analysis identifying both parameters as strong prognostic factors for survival, LR and DM (P<0.0001). In conclusion, postoperative plasma TIMP-1 predicts patient outcome both alone and in combination with CEA. Postoperative TIMP-1 may be a marker of residual disease after primary surgery for CRC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809030     DOI: 10.1016/j.ejca.2006.01.058

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

Review 1.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.

Authors:  Keith Brew; Hideaki Nagase
Journal:  Biochim Biophys Acta       Date:  2010-01-15

2.  Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.

Authors:  Markus Wagner; Vincent Roh; Michael Strehlen; Alexander Laemmle; Deborah Stroka; Bernhard Egger; Markus Trochsler; Kelly K Hunt; Daniel Candinas; Stephan A Vorburger
Journal:  J Gastrointest Surg       Date:  2009-06-30       Impact factor: 3.452

3.  Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.

Authors:  Bodil E Engelmann; Annika Loft; Andreas Kjær; Hans J Nielsen; Thomas A Gerds; Eric V Benzon; Nils Brünner; Ib J Christensen; Susanne H Hansson; Niels H Holländer; Michael H Kristensen; Johan Löfgren; Elena Markova; Carsten Sloth; Liselotte Højgaard
Journal:  Oncologist       Date:  2014-01-22

4.  TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.

Authors:  Karen-Lise Garm Spindler; Ib Jarle Christensen; Hans Jørgen Nielsen; Anders Jakobsen; Nils Brünner
Journal:  Tumour Biol       Date:  2015-01-23

5.  TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.

Authors:  Sven Mahner; Linn Woelber; Christine Eulenburg; Joerg Schwarz; Walter Carney; Fritz Jaenicke; Karin Milde-Langosch; Volkmar Mueller
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

Review 6.  Premetastatic niche formation in the liver: emerging mechanisms and mouse models.

Authors:  Achim Krüger
Journal:  J Mol Med (Berl)       Date:  2015-09-24       Impact factor: 4.599

7.  The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer.

Authors:  Irena Oblak; Vaneja Velenik; Franc Anderluh; Barbara Mozina; Janja Ocvirk
Journal:  Radiol Oncol       Date:  2013-05-21       Impact factor: 2.991

8.  Profile of Expression of Genes Encoding Matrix Metallopeptidase 9 (MMP9), Matrix Metallopeptidase 28 (MMP28) and TIMP Metallopeptidase Inhibitor 1 (TIMP1) in Colorectal Cancer: Assessment of the Role in Diagnosis and Prognostication.

Authors:  Zbigniew Lorenc; Dariusz Waniczek; Katarzyna Lorenc-Podgórska; Wiktor Krawczyk; Maciej Domagała; Mateusz Majewski; Urszula Mazurek
Journal:  Med Sci Monit       Date:  2017-03-15

9.  Analysis of potential genes and pathways associated with the colorectal normal mucosa-adenoma-carcinoma sequence.

Authors:  Zhuoxuan Wu; Zhen Liu; Weiting Ge; Jiawei Shou; Liangkun You; Hongming Pan; Weidong Han
Journal:  Cancer Med       Date:  2018-04-16       Impact factor: 4.452

10.  Positron emission tomography/computed tomography for optimized colon cancer staging and follow up.

Authors:  Bodil Elisabeth Engelmann; Annika Loft; Andreas Kjær; Hans Jørgen Nielsen; Anne Kiil Berthelsen; Tina Binderup; Kim Brinch; Nils Brünner; Thomas Alexander Gerds; Gunilla Høyer-Hansen; Michael Holmsgaard Kristensen; Engin Yeter Kurt; Jan Erik Latocha; Gunnar Lindblom; Carsten Sloth; Liselotte Højgaard
Journal:  Scand J Gastroenterol       Date:  2013-11-29       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.